TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04023331
Drug: 64Cu-SARTATE
Normalized name: 64Cu-dotatate
DrugBank: Cu-64 sartate (DB18170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64Cu-labelled MeCOSar-Tyr3-octreotate
Study: NCT00614159
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight based dosage for Peds subjects, used for duration of the endoscopy.
Study: NCT00614159
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight based dosage for Peds subjects, used for duration of the endoscopy.
Study: NCT01857193
Drug: ribociclib (LEE011)
DrugBank: Ribociclib (DB11730)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
Study: NCT01857193
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
Study: NCT01857193
Drug: Everolimus (RAD001)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
Study: NCT04232397
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anlotinib 8mg qd po
Study: NCT02835742
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02808793
Drug: AK002
Normalized name: MONOCLONAL ANTIBODY AK002
DrugBank: Lirentelimab (DB16728)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01713608
Drug: OZ439
Normalized name: Artefenomel
DrugBank: Artefenomel (DB11809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 x mg once daily for 3 days with milk
Study: NCT00579098
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg tablet taken by mouth daily for 90 days
Study: NCT03023462
Drug: Ondansetron and Droperidol
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
Study: NCT03023462
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic for the block
Study: NCT01868997
Drug: teprotumumab
Normalized name: Teprotumumab
DrugBank: Teprotumumab (DB06343)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01254331
Drug: tocilizumab [RoActemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
Study: NCT00098956
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00098956
Drug: 7-hydroxystaurosporine
Normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00152620
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00152620
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00591994
Drug: piribedil
Normalized name: piribedil
DrugBank: Piribedil (DB12478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg once a day, after lunch 3 month therapy
Study: NCT02215096
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
Study: NCT00704678
Drug: Sevelamer HCl
Normalized name: SEVELAMER HCL
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.6 g tid
Study: NCT00704678
Drug: Sevelamer HCl
Normalized name: SEVELAMER HCL
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5 g tid
Study: NCT00704678
Drug: Sevelamer HCl
Normalized name: SEVELAMER HCL
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.8 g tid
Study: NCT03784703
Drug: Atorvastatin 40 Mg Oral Tablet
Normalized name: atorvastatin 40 mg oral tablet
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg per day atorvastatin (ATROVA group, n= 80) for 6 months
Study: NCT03877549
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Additional of two different doses of dexamethasone via the epidural catheter during surgical closure after cesarean section
Study: NCT03903796
Drug: HS-10234
Normalized name: sodium fluoride 0.00234 MG/MG
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
Study: NCT03903796
Drug: TDF
Normalized name: moxetumomab pasudotox-tdfk
DrugBank: Moxetumomab pasudotox (DB12688)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
Study: NCT01444131
Drug: Varenicline, Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: active nicotine patches added to varenicline.
Study: NCT01444131
Drug: Varenicline and Placebo Patch
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo nicotine patches added to varenicline.
Study: NCT04118842
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
Study: NCT04118842
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
Study: NCT03272217
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 1200 mg (flat dose) IV every 21 days
Study: NCT03272217
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg IV every 21 days
Study: NCT03935295
Drug: AbobotulinumtoxinA
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Paraspinal abobotulinumtoxinA injections (compared to placebo)
Study: NCT00658814
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC during induction; given SC during consolidation and maintenance
Study: NCT00658814
Drug: Gemtuzumab Ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01997853
Drug: Omega 3 fatty acid
Normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
Study: NCT04487106
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV or SC
Study: NCT04487106
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04487106
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01126086
Drug: otamixaban XRP0673
Normalized name: Otamixaban
DrugBank: Otamixaban (DB06635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous
Study: NCT02551861
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02551861
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02551861
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00934479
Drug: Lubiprostone
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
Study: NCT02002832
Drug: Lurasidone tablets
Normalized name: lurasidone Oral Tablet
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
Study: NCT02002832
Drug: Risperidone tablets
Normalized name: Risperidone Tablets
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
Study: NCT03540030
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03540030
Drug: toradol
Normalized name: Toradol
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT02573909
Drug: Oxycodone intravenously
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone intravenously 0,1mg/kg
Study: NCT03540030
Drug: regional block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03540030
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03540030
Drug: IV lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03540030
Drug: rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03540030
Drug: vecuronium
Normalized name: Vecuronium
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03540030
Drug: sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT03540030
Drug: desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
Study: NCT00027716
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00447005
Drug: Axitinib (AG-013736)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AG-013736 5mg twice daily \[BID\]
Study: NCT02573909
Drug: Oxycodone epidurally
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 0,1 mg epidurally
Study: NCT04559607
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab: 200mg, iv, Q3W
Study: NCT04559607
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib: 250m, po, QD
Study: NCT04652427
Drug: Dexmedetomidine Hydrochloride 0.1 MG/ML
Normalized name: dexmedetomidine hydrochloride 0.1 MG/ML
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
Study: NCT04652427
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At least 15 min prior to anesthesia is sedated by the study drug given according to the administration protocol, an alert/sedative score (OAA/S) is performed at the end of the drug load dose administration, and then the maintenance-giving phase is then performed at the end of the operation with an OAA/S score every 5 min. Anestheticing can be performed after the required level of sedation has been reached. OAA/S 4 should always be maintained during drug administration.
Study: NCT02058173
Drug: 150 mg/daily chloroquine compare to placebo for 12 week
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02058173
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02985437
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04286399
Drug: Renin-angiotensin-aldosterone system inhibitors
DrugBank: Aldosterone (DB04630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Study: NCT04286399
Drug: SGLT2 Inhibitor - Sodium Glucose Cotransporter Subtype 2 Inhibitor Product
Normalized name: Fibrinolysis inhibitor
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Research participants in the intensive therapy arm should be strongly encouraged to follow the intensive treatment strategy. Every attempt should be made to up-titrate RAS-antagonists and beta-blockers (max dosage, unless contraindicated) as well as preferentially use SGLT2i (standard dosage, as required) throughout the trial.
Study: NCT00365222
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: temozolomide 75 mg/m2 /d
Study: NCT02388178
Drug: Experimental toothpaste containing fluoride and amino acid (arginine)
Normalized name: sodium fluoride Toothpaste
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
Study: NCT01354587
Drug: Hizentra
Normalized name: Hizentra
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
Study: NCT01392898
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide 1.8 mg q.d.
Study: NCT01392898
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: insulin dosed according titration scheme
Study: NCT00601198
Drug: Amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
Study: NCT01088750
Drug: vinblastine sulfate
Normalized name: Vinblastine Sulfate
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02846831
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study: NCT02219321
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
Study: NCT02655133
Drug: Pentaglobin®
DrugBank: Pentaglobin (DB15865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
Study: NCT03945721
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring.
Study: NCT04534582
Drug: HLX14
Normalized name: Lanadelumab
DrugBank: Lanadelumab (DB14597)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: healthy volunteers receive HLX14 (60mg) once
Study: NCT03956888
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
Study: NCT02389309
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02389309
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04551885
Drug: FT516
Normalized name: FT516
DrugBank: FT516 (DB15732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Interventional Therapy
Study: NCT01491971
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04551885
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody
Study: NCT04551885
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lympho-conditioning agent
Study: NCT04551885
Drug: IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic response modifier
Study: NCT03939026
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for lymphodepletion
Study: NCT03617484
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle.
Study: NCT03617484
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
Study: NCT03127046
Drug: Aceclofenac
Normalized name: Aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral single dose administration of aceclofenac 200mg
Study: NCT03127046
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral single dose administration of aceclofenac 200mg
Study: NCT03991832
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib is a drug that blocks a protein called poly (ADP-ribose) polymerase (PARP). PARP is important in the growth and spread of cancer cells. Because of this, blocking PARP from working is expected to stop the growth of or shrink cancer cells.
Study: NCT03127046
Drug: Aceclofenac and Esomeprazole
Normalized name: aceclofenac
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
Study: NCT01137396
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 400mg PO QDaily following up-titration for \~8weeks
Study: NCT03991832
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.
Study: NCT03754725
Drug: Deferiprone pill
Normalized name: deferiprone Pill
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg of deferiprone (oral) BID (15 mg/Kg)
Study: NCT00628056
Drug: Perhexiline
Normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks